1.60
0.03 (1.91%)
| Previous Close | 1.57 |
| Open | 1.58 |
| Volume | 2,387,738 |
| Avg. Volume (3M) | 916,055 |
| Market Cap | 173,036,800 |
| Price / Sales | 5.53 |
| Price / Book | 0.930 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Operating Margin (TTM) | -152.75% |
| Diluted EPS (TTM) | -1.71 |
| Quarterly Revenue Growth (YOY) | -47.60% |
| Total Debt/Equity (MRQ) | 1.67% |
| Current Ratio (MRQ) | 3.99 |
| Operating Cash Flow (TTM) | -20.07 M |
| Levered Free Cash Flow (TTM) | -59.12 M |
| Return on Assets (TTM) | -15.72% |
| Return on Equity (TTM) | -84.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | Aclaris Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | -3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.70 |
|
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 2.66% |
| % Held by Institutions | 82.44% |
| 52 Weeks Range | ||
| Median | 15.00 (837.50%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 07 Mar 2025 | 15.00 (837.50%) | Buy | 1.83 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| WALKER NEAL | - | 1.34 | -2,975 | -3,987 |
| Aggregate Net Quantity | -2,975 | |||
| Aggregate Net Value ($) | -3,987 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1.34 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WALKER NEAL | Officer | 01 May 2025 | Disposed (-) | 2,975 | 1.34 | 3,987 |
| WALKER NEAL | Officer | 01 May 2025 | Option execute | 9,467 | - | - |
| Date | Type | Details |
|---|---|---|
| 09 May 2025 | Announcement | Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series |
| 08 May 2025 | Announcement | Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 29 Apr 2025 | Announcement | Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer |
| 22 Apr 2025 | Announcement | Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody |
| 04 Mar 2025 | Announcement | Aclaris Therapeutics to Participate in Two March Healthcare Conferences |
| 27 Feb 2025 | Announcement | Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update |
| 12 Feb 2025 | Announcement | New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |